Australian Pharmaceuticals & Biotech High Insider Buying

CSL

Market Cap: AU$58.9b

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Telix Pharmaceuticals

Market Cap: AU$5.5b

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.

Racura Oncology

Market Cap: AU$428.3m

Operates as a Phase 3 clinical biopharmaceutical company for cancer care.

Starpharma Holdings

Market Cap: AU$309.5m

A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.

Orthocell

Market Cap: AU$230.1m

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.

Nyrada

Market Cap: AU$105.3m

A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.

Arovella Therapeutics

Market Cap: AU$79.8m

A biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.

Entropy Neurodynamics

Market Cap: AU$57.1m

A clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.

Nexsen

Market Cap: AU$56.1m

Operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications.

Neurizon Therapeutics

Market Cap: AU$50.0m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.

Imugene

Market Cap: AU$43.7m

A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Patrys

Market Cap: AU$26.7m

Develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases.

Peak Processing

Market Cap: AU$22.6m

Manufactures, distributes, and sells recreational cannabis products in Canada and the United States.

Ceryvyn Therapeutics

Market Cap: AU$16.4m

A clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States.

IDT Australia

Market Cap: AU$13.7m

Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States.

Firebrick Pharma

Market Cap: AU$9.1m

Engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.

Epsilon Healthcare

Market Cap: AU$8.6m

Engages in the healthcare business in Australia.

Percheron Therapeutics

Market Cap: AU$5.3m

Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.

Cynata Therapeutics

Market Cap: AU$3.2m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Chimeric Therapeutics

Market Cap: AU$2.8m

A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.